Education
About Us
Working with TipRanks
Follow Us
Nuvation Bio (NUVB)
NYSE:NUVB
NUVB Stock Chart & Stats
$8.52
-$0.19(-5.85%)
At close: 4:00 PM EST
$8.52
-$0.19(-5.85%)
Day’s Range― - ―
52-Week Range$1.54 - $8.95
Previous CloseN/A
Volume977.37K
Average Volume (3M)8.63M
Market Cap
$2.98B
Enterprise Value$1.18B
Total Cash (Recent Filing)$549.04M
Total Debt (Recent Filing)$57.55M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Mar 05, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding342,833,440
10 Day Avg. Volume6,480,565
30 Day Avg. Volume8,627,993
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.54
Price to Sales (P/S)90.81
P/FCF Ratio-5.48
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue44.06
Enterprise Value/Gross Profit81.20
Enterprise Value/Ebitda-5.48
Forecast
1Y Price Target
$11.38Price Target Upside33.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.6
Revenue Forecast (FY)$54.74M
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyIBTROZI's efficacy profile, with high response rates and a long median duration of response, positions it as best-in-class compared to competitors.
Market PerformanceThe projected peak penetration for IBTROZI in the market is increased to 45%, indicating strong expected market performance.
Regulatory And ApprovalFull approval in line agnostic ROS1+ NSCLC removes regulatory risks, and focus now turns to commercialization.
Bears Say
Clinical Trials And DevelopmentNuvation announced that it is discontinuing development of NUV-1511 due to insufficient consistency in efficacy across cohorts.
Financial RisksNuvation is not planning to conduct a pivotal trial in non-enhancing grade 2 IDH1-mutant glioma due to the high cost of over $100 million, impacting the scope of their clinical trials.
Market SentimentShort interest stands at 15.5% of the float, indicating a significant level of bearish sentiment in the market.
Nuvation Bio News
NUVB FAQ
What was Nuvation Bio’s price range in the past 12 months?
Nuvation Bio lowest stock price was $1.54 and its highest was $8.95 in the past 12 months.
What is Nuvation Bio’s market cap?
Nuvation Bio’s market cap is $2.98B.
When is Nuvation Bio’s upcoming earnings report date?
Nuvation Bio’s upcoming earnings report date is Mar 05, 2026 which is in 76 days.
How were Nuvation Bio’s earnings last quarter?
Nuvation Bio released its earnings results on Nov 03, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.169 by $0.009.
Is Nuvation Bio overvalued?
According to Wall Street analysts Nuvation Bio’s price is currently Undervalued.
Does Nuvation Bio pay dividends?
Nuvation Bio does not currently pay dividends.
What is Nuvation Bio’s EPS estimate?
Nuvation Bio’s EPS estimate is -0.1.
How many shares outstanding does Nuvation Bio have?
Nuvation Bio has 342,833,440 shares outstanding.
What happened to Nuvation Bio’s price movement after its last earnings report?
Nuvation Bio reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.169. Following the earnings report the stock price went down -6.576%.
Which hedge fund is a major shareholder of Nuvation Bio?
Currently, no hedge funds are holding shares in NUVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvation Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.38 (33.57% Upside)
$11.38 (33.57% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 782.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
221.93%
12-Months-Change
Fundamentals
Return on Equity
-52.49%
Trailing 12-Months
Asset Growth
5.25%
Trailing 12-Months
Company Description
Nuvation Bio
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
NUVB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted a successful launch of IBTROZI with strong adoption and expansion in markets outside the U.S., alongside robust financial performance. However, challenges related to high costs and strategic decisions in the IDH1 program were noted. The positive growth and approval metrics for IBTROZI outweigh these challenges.View all NUVB earnings summariesNUVB Stock 12 Month Forecast
Average Price Target
$11.38
▲(33.57% Upside)
Technical Analysis
Nektar Therapeutics
―
Precigen
―
Wave Life Sciences
―
Enliven Therapeutics
―
Praxis Precision Medicines
―
Ownership Overview
17.60% Insiders
15.89% Mutual Funds
21.05% Other Institutional Investors
36.07% Public Companies and Individual Investors